TMAO treatment increases the release of intracellular Ca2+ induced by angiotensin II in afferent arteries and vascular smooth muscle cells via the PERK/ROS/CaMKII/plc-β3 axis, thereby promoting angiotensin II-induced vasoconstriction and hypertension [36]. Here, AGT is linked to hypertensive disorder.